TOVX

Theriva Biologics, Inc. (TOVX) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Theriva Biologics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, primarily developing its lead oncolytic adenovirus candidate, VCN-01 (zabilugene almadenorepvec), for pancreatic cancer and retinoblastoma. The company also holds assets in gastrointestinal diseases (SYN-004, SYN-020), though SYN-020 was recently out-licensed. The company is classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Significant Expense Reduction: Net loss decreased by approximately 70% year-over-year for the six-month period. This is primarily driven by a $9.2 million non-cash charge in the prior year (Q2 2025) related to the fair value adjustment of contingent consideration following the achievement of primary endpoints in the VIRAGE Phase 2b trial. No such charge occurred in the current period.
• Revenue Recognition: The company recognized $300,000 in license revenue in Q2 2026 from an upfront payment received from Rasayana Therapeutics for the exclusive worldwide license of SYN-020. There was no revenue in the comparable prior periods.
• Operating Expenses: General and Administrative (G&A) expenses dropped from $12.6 million (YTD 2025) to $4.1 million (YTD 2026). Research and Development (R&D) expenses decreased from $4.9 million to $1.6 million, reflecting the completion of certain clinical trials and a strategic workforce reduction implemented in late 2025.
• Capital Structure: The company issued approximately 10.2 million shares under its At-The-Market (ATM) program during the six months ended June 30, 2026, raising net proceeds of $2.3 million.

Guidance, Outlook, and Risks

• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for the next twelve months without additional capital. The company has an accumulated deficit of $364 million and relies on equity/debt financing or strategic partnerships.
• Cash Runway: Management estimates current cash ($11.3 million) is sufficient to fund operations into the first quarter of 2027. This runway covers overhead, a Phase 2a study in pancreatic cancer (VIRAGE2), regulatory interactions for retinoblastoma, and limited preclinical work. It is not sufficient for a full Phase 3 trial or further development of SYN-004 without new funding.
• Clinical Milestones:
  • VCN-01 (Pancreatic Cancer): Received FDA agreement on Phase 3 trial design. Authorized to initiate VIRAGE2 (Phase 2a) in Spain to evaluate increased dosing frequency.
  • VCN-01 (Retinoblastoma): Planning regulatory interactions for a pivotal Phase 2/3 trial with topotecan. Estimated cost is $9 million; first patient enrollment expected in January 2027.
  • SYN-004: Development paused; the company does not intend to fund the final cohort without grant funding or a partner.
• Contingent Liability Risk: The company owes a deferred milestone payment of $5.0 million to Grifols Innovation. Payment of this amount would significantly deplete cash reserves and materially impact liquidity.
• Strategic Alternatives: The company is actively exploring strategic alternatives, including mergers, reverse mergers, or business combinations, to maximize shareholder value and secure funding.

Investor Verification Checklist

• Cash Burn Rate: Verify the accuracy of the "first quarter 2027" runway estimate given the $5.0 million deferred milestone payment to Grifols.
• Financing Plans: Confirm the status of ongoing discussions with institutional investors and the feasibility of utilizing the ATM program given current market conditions and SEC limitations on non-affiliate market value.
• VCN-01 Phase 3 Funding: Assess the likelihood of securing the significant capital required for a Phase 3 trial in pancreatic cancer, which is not covered by current cash.
• Strategic Review: Monitor disclosures regarding the strategic review process for potential mergers or asset sales, as this is a primary mitigation strategy for the going concern risk.
• SYN-020 Milestones: Track the progress of Rasayana Therapeutics in developing SYN-020 to determine the probability of future milestone payments ($16M development, $22M sales).